Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B
2
) into Milk
-
Published:2007-02-15
Issue:4
Volume:27
Page:1247-1253
-
ISSN:0270-7306
-
Container-title:Molecular and Cellular Biology
-
language:en
-
Short-container-title:Mol Cell Biol
Author:
van Herwaarden Antonius E.1, Wagenaar Els1, Merino Gracia1, Jonker Johan W.1, Rosing Hilde2, Beijnen Jos H.2, Schinkel Alfred H.1
Affiliation:
1. Division of Experimental Therapy, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands 2. Department of Pharmacy and Pharmacology, Slotervaart Hospital, 1066 EC Amsterdam, The Netherlands
Abstract
ABSTRACT
The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation. We here demonstrate that BCRP is responsible for pumping riboflavin (vitamin B
2
) into milk, thus supplying the young with this important nutrient. In
Bcrp1
−/−
mice, milk secretion of riboflavin was reduced >60-fold compared to that in wild-type mice. Yet, under laboratory conditions,
Bcrp1
−/−
pups showed no riboflavin deficiency due to concomitant milk secretion of its cofactor flavin adenine dinucleotide, which was not affected. Thus, two independent secretion mechanisms supply vitamin B
2
equivalents to milk. BCRP is the first active riboflavin efflux transporter identified in mammals and the first transporter shown to concentrate a vitamin into milk. BCRP activity elsewhere in the body protects against xenotoxins by reducing their absorption and mediating their excretion. Indeed, Bcrp1 activity increased excretion of riboflavin into the intestine and decreased its systemic availability in adult mice. Surprisingly, the paradoxical dual utilization of BCRP as a xenotoxin and a riboflavin pump is evolutionarily conserved among mammals as diverse as mice and humans. This study establishes the principle that an ABC transporter can transport a vitamin into milk and raises the possibility that other vitamins and nutrients are likewise secreted into milk by ABC transporters.
Publisher
American Society for Microbiology
Subject
Cell Biology,Molecular Biology
Reference22 articles.
1. Allen, J. D., A. van Loevezijn, J. M. Lakhai, M. A. van der Valk, O. van Tellingen, G. Reid, J. H. M. Schellens, G. J. Koomen, and A. H. Schinkel. 2002. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther.1:417-425. 2. Bardelmeijer, H. A., J. H. Beijnen, K. R. Brouwer, H. Rosing, W. J. Nooijen, J. H. M. Schellens, and O. van Tellingen. 2000. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res6:4416-4421. 3. Bosch, T. M., L. M. Kjellberg, A. Bouwers, B. P. Koeleman, J. H. M. Schellens, J. H. Beijnen, P. H. Smits, and I. Meijerman. 2005. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am. J. Pharmacogenom.5:123-131. 4. Breedveld, P., N. Zelcer, D. Pluim, Ö. Sönmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. M. Schellens. 2004. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res64:5804-5811. 5. Breedveld, P., J. H. Beijnen, and J. H. M. Schellens. 2006. Use of P-gp (ABCB1) and BCRP (ABCG2) inhibitors to improve oral bioavailability and brain penetration of anticancer drugs. Trends Pharmacol. Sci.27:17-24.
Cited by
180 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|